Starbucks, Gilead And Ambev Are At 52-Week Lows: Should You Buy The Dip?
Starbucks, Gilead And Ambev Are At 52-Week Lows: Should You Buy The Dip?
Capital market investors often look for entry points, hidden gems, and value bets. Quality stocks trading at or around their 52-week low levels offer one such opportunity window.
資本市場投資者經常尋找切入點、隱藏的寶石和價值下注。交易價格處於或接近52周低點的優質股票提供了這樣的機會窗口。
We looked at established companies that, recently, made new 52-week lows. We point readers' attention to three such stocks, with $35 billion market capitalizations. These are: Starbucks Corp (NASDAQ:SBUX), Gilead Sciences (NASDAQ:GILD) and Ambev SA (NYSE:ABEV).
我們研究了最近創下52周新低的老牌公司。我們將讀者的注意力引向三隻這樣的股票，市值爲350億美元。它們是：星巴克公司（納斯達克股票代碼：SBUX）、吉利德科學（納斯達克股票代碼：GILD）和Ambev SA（紐約證券交易所代碼：ABEV）。
Starbucks
星巴克
Trading at around $86.83, the coffee franchise's stock could potentially offer a buy-the-dip opportunity. The Seattle-based company's shares command a market cap of over $98 billion on the stock market and sport an average three-month trading volume of 8.49 million.
這家咖啡專營店的股票交易價格約爲86.83美元，有可能提供逢低買入的機會。這家總部位於西雅圖的公司的股票市場市值超過980億美元，三個月的平均交易量爲849萬股。
The stock also offers, to its investors, a dividend yield of 2.63%.
該股還向其投資者提供2.63％的股息收益率。
Wells Fargo, TD Cowen, and TD Cowen released the last three analyst ratings on April 1, April 1, and March 19, 2024, respectively. These ratings suggest an average price target of $102.33 for Starbucks Corp, implying a potential upside of 17.23% based on the assessments of these three analysts.
富國銀行、道明考恩和道明考恩分別於2024年4月1日、4月1日和3月19日發佈了最近三次分析師評級。這些評級表明，星巴克公司的平均目標股價爲102.33美元，根據這三位分析師的評估，這意味着潛在的上漲幅度爲17.23％。
Also Read: $100 Invested In This Stock 15 Years Ago Would Be Worth $1,600 Today
另請閱讀：15年前投資這隻股票的100美元今天的價值爲1,600美元
Gilead Sciences
吉利德科學
Trading at around $69.32, this biopharma stock is currently trading about its 52-week lows. The company gained widespread recognition for its development of antiretroviral drugs for the treatment of HIV/AIDS, including medications such as Truvada, Atripla, and Descovy.
該生物製藥股票的交易價格約爲69.32美元，目前的交易價格約爲52周低點。該公司因開發用於治療艾滋病毒/艾滋病的抗逆轉錄病毒藥物而獲得廣泛認可，其中包括Truvada、Atripla和Descovy等藥物。
Gilead stock offers a robust dividend yield of 4.43%.
吉利德股票的股息收益率強勁，爲4.43％。
Wells Fargo, Mizuho, and Truist Securities recently released the last three analyst ratings. These assessments collectively suggest an average price target of $83.33 for Gilead stock.
富國銀行、瑞穗和Truist Securities最近發佈了最近三個分析師評級。這些評估共同表明，吉利德股票的平均目標股價爲83.33美元。
Based on these ratings, there is an implied 20.16% upside potential for the company.
根據這些評級，該公司的上行潛力爲20.16％。
Ambev
Ambev
Ambev SA is widely renowned for its portfolio of beer brands, including popular labels such as Skol, Brahma, Antarctica, and Budweiser. Trading at $2.40, Ambev stock is near-about its 52-week low level of $2.36. The stock also offers a juicy dividend yield of 6.26%.
Ambev SA以其啤酒品牌組合而聞名，其中包括Skol、Brahma、南極洲和百威啤酒等熱門品牌。Ambev股票的交易價格爲2.40美元，接近其52周低點2.36美元。該股還提供6.26％的豐厚股息收益率。
Based on the analysis of the 8 latest analyst ratings, Ambev SA has a consensus price target of $2.2. The most recent ratings were issued by Barclays, Jefferies, and Bernstein on March 4, 2024, Nov. 22, 2023, and May 24, 2023, respectively.
根據對8個最新分析師評級的分析，Ambev SA的共識目標股價爲2.2美元。最新的評級分別由巴克萊、傑富瑞和伯恩斯坦於2024年3月4日、2023年11月22日和2023年5月24日發佈。
These assessments collectively indicate an average price target of $3.2 for Ambev stock. Consequently, there's an implied 32.51% upside potential for the company based on these three analyst ratings.
這些評估共同表明，Ambev股票的平均目標股價爲3.2美元。因此，根據這三個分析師評級，該公司的上行潛力爲32.51％。
These findings suggest that these quality stocks may present lucrative investment opportunities, offering potential upside for investors in the coming months.
這些發現表明，這些優質股票可能帶來豐厚的投資機會，爲投資者在未來幾個月內提供潛在的上行空間。